Supplements That May Help Manage Erythrocytosis From Testosterone Cypionate

Does any supplement help erythrocytosis from testosterone cypionate?

A PubMed search on testosterone, erythrocytosis and diet, hydration, supplements or exercise found no study testing any of them as a way to lower hematocrit in men on testosterone, including naringin, IP6, curcumin, quercetin or fish oil. That is a gap in the evidence, not a finding of benefit or of harm.

The question arises because of the biology. In a 6-month randomized trial of testosterone gel against placebo in older men with mobility limitation, the rise in hemoglobin and hematocrit came with higher erythropoietin and lower ferritin and hepcidin at 1 and 3 months [5]. It did not test supplements.

How much does testosterone cypionate raise hematocrit?

A network meta-analysis in the Journal of Urology pooled 29 placebo-controlled randomized trials covering 3,393 men. Intramuscular testosterone enanthate or cypionate raised mean hematocrit by 4.0% over placebo (95% CI 2.9 to 5.1), compared with 3.0% for gel and 1.4% for patch [3].

A retrospective review of 178 hypogonadal men followed for 3 years found hematocrit above 50% in 66.7% of those on injectable testosterone, 12.8% on gels and 35.1% on pellets. The injection group was younger (mean 42.5 versus about 54 years) with a higher starting hematocrit, and the study was not randomized [4]. A separate review puts the risk of erythrocytosis, defined there as hematocrit above 0.52, at 315% higher than controls [6], and another reports that short-acting injectables carry the highest incidence [7].

What the Depo-Testosterone label says

The label lists polycythemia among hematologic adverse reactions, and its clinical pharmacology section states that androgens stimulate red blood cell production by enhancing production of erythropoietic stimulation factor. It says to check hemoglobin and hematocrit periodically during long-term use, and notes that increased red blood cell mass may increase the risk of thromboembolic events. Venous thromboembolism has been reported with testosterone products, and the label says to discontinue treatment if one is suspected [1].

What is described instead of supplements

A 2023 clinical consultation guide for managing erythrocytosis in men on testosterone says providers should decrease or discontinue therapy when hematocrit exceeds 54%, until it normalizes [2]. A 2022 review says clinicians will often adjust testosterone dosing, stop therapy, order phlebotomy, or combine these [12]. The Endocrine Society guideline recommends against starting testosterone in men who already have an elevated hematocrit and recommends monitoring hematocrit in the first year of treatment [8].

For erythrocytosis in general, which is not specific to testosterone, a 2025 review says phlebotomy should be considered for symptom control, and another 2025 review says there are currently no evidence-based treatment guidelines and that low-dose aspirin and/or phlebotomy might be considered on an individualized basis [9][10]. A 2025 systematic review of drug-induced erythrocytosis found no clear consensus among clinicians on diagnosis or management, and reported thromboembolic events in up to 2.7% of men on testosterone therapy [11].